for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover JAMA The Journal of the American Medical Association
  [SJR: 6.44]   [H-I: 549]   [1647 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 0098-7484 - ISSN (Online) 1538-3598
   Published by American Medical Association Homepage  [13 journals]
  • Highlights for January 16, 2018
    • PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • What Is the Appropriate Response to Evolving Norms of Obesity'
    • Authors: Burke MA; Heiland FW.
      Abstract: This Viewpoint discusses shifts in social norms toward acceptance of obesity as normal and proposes harnessing the same peer effects that have destigmatized obesity to promote and spread healthy behaviors.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Toward Precision Approaches for the Prevention and Treatment of Obesity
    • Authors: Yanovski SZ; Yanovski JA.
      Abstract: This Viewpoint discusses the prospects for treatment of obesity through identification of genetic, metabolic, behavioral, and environmental risk factors and an understanding of factors that account for variability in the success of treatment.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Counting Calories as an Approach to Achieve Weight Control
    • Authors: Guth E.
      Abstract: This Viewpoint discusses approaches that clinicians can take when advising overweight or obese patients to achieve weight control via calorie reduction.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Can the Government Require Health Warnings on Sugar-Sweetened Beverage
           Ads'
    • Authors: Pomeranz JL; Mozaffarian D, Micha R.
      Abstract: This Viewpoint uses the 2017 Ninth Circuit ruling enjoining San Francisco from requiring a health warning statement on sugar-sweetened beverages to discuss modifications that would make the warnings legally justifiable.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Taxes and Sugar-Sweetened Beverages
    • Authors: Powell LM; Maciejewski ML.
      Abstract: This Viewpoint discusses the merits and challenges to implementing taxes on sugar-sweetened beverages aimed at reducing their consumption in an effort to curb US obesity rates.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Which Is More Important for Health: Fitness or Fatness'
    • Authors: Kennedy A; Lavie CJ, Blair SN.
      Abstract: This Viewpoint reviews evidence comparing the relative importance of cardiorespiratory fitness and obesity with all-cause and cardiovascular disease–related mortality, and calls for accurate measures of physical activity and fitness in future studies investigating associations between obesity and mortality.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Starting Discussions With Patients About Health Policy Changes That Will
           Affect Their Care
    • Authors: Avorn J.
      Abstract: In this essay, Jerry Avorn considers physicians’ social responsibility to initiate discussions with their patients about changes in health policy proposed by politicians that will affect patients' quality and continuity of care.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Comparing the Outcomes of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass
           for Severe Obesity
    • Authors: Arterburn D; Gupta A.
      Abstract: Over the past decade there has been a rapid shift in bariatric procedure use worldwide, with the sleeve gastrectomy replacing the Roux-en-Y gastric bypass as the procedure of choice in most patients with severe obesity. The sleeve gastrectomy is less technically complex than the bypass procedure, and involves a 70% vertical gastric resection with no intestinal bypass. The use of the sleeve gastrectomy was spurred by short-term evidence suggesting that weight loss was nearly equivalent to bypass, while conferring a lower risk of perioperative complications. However, the popularity of sleeve gastrectomy has outpaced data from rigorous comparative effectiveness research studies, and the durability and long-term safety of sleeve gastrectomy vs bypass remain topics of debate.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Reimagining Obesity in 2018 A JAMA Theme Issue on Obesity
    • Authors: Livingston EH.
      Abstract: Six years ago, when JAMA last published a theme issue on obesity, there was optimism that progress was being made in preventing and treating obesity. As time has passed, so too has the optimism, as reports continued to show that the prevalence of obesity was increasing and, most important, rapidly increasing in children. A year and a half ago, there was a call to reconsider obesity and view it in new ways with the hope of better managing this very consequential clinical problem. In response, JAMA has revisited obesity in the form of a theme issue.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Five-Year Outcomes of Laparoscopic Sleeve Gastrectomy vs Gastric Bypass
           for Morbid Obesity
    • Authors: Salminen P; Helmiö M, Ovaska J, et al.
      Abstract: This study reports 5-year weight loss outcomes for participants in the SLEEVEPASS equivalence trial with morbid obesity managed with laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Effect of Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Morbid Obesity
    • Authors: Peterli R; Wölnerhanssen B, Peters T, et al.
      Abstract: This randomized clinical trial compares the effects of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on 5-year excess weight loss in patients with morbid obesity.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Control of Cardiovascular Disease Risk Factors 5 Years After Gastric
           Bypass for Type 2 Diabetes
    • Authors: Ikramuddin S; Korner J, Lee W, et al.
      Abstract: This report describes 5-year blood pressure, Hemoglobin A1c, and lipid levels among participants previously randomized to Roux-en-Y gastric bypass surgery vs no surgery for management of obesity and type 2 diabetes.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Association Between Bariatric Surgery vs Usual Care Obesity Management and
           All-Cause Mortality
    • Authors: Reges O; Greenland P, Dicker D, et al.
      Abstract: This cohort study uses Israeli electronic health record data to compare mortality of obese adult patients who underwent bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy) vs obese adults receiving nonsurgical usual care management.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Complications After Bariatric Surgery vs Medical Obesity Treatment
    • Authors: Jakobsen G; Småstuen M, Sandbu R, et al.
      Abstract: This cohort study uses Norwegian registry data to compare long-term changes in hypertension, diabetes, depression, and opioid use among patients with severe obesity treated with bariatric surgery or specialized medical treatment.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Long-term Outcomes Following Bariatric Surgery
    • Authors: Shubeck S; Dimick JB, Telem DA.
      Abstract: This commentary discusses a study published in JAMA Surgery reporting 7-year weight and health outcomes for patients in the Longitudinal Assessment of Bariatric Surgery (LABS) Study who underwent Roux-en-Y gastric bypass or laparoscopic adjustable gastric banding.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Cost to Consumers of a Sugar-Sweetened Beverage Tax at the Philadelphia
           Airport
    • Authors: Cawley J; Willage B, Frisvold D.
      Abstract: This study estimates how much the 1.5¢-per-ounce tax on sugar-sweetened beverages in Philadelphia raised retail prices of soft drinks at the Philadelphia International Airport 1 month after implementation.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast
           Cancer
    • Authors: Uno H; Hassett MJ, Wei L.
      Abstract: To the Editor Dr Giuliano and colleagues analyzed 10-year survival and disease-free survival data for women with breast cancer who had breast-conserving surgery followed either by sentinel lymph node dissection (SLND) alone or axillary lymph node dissection (ALND). The study was designed to assess whether SLND was noninferior to ALND with a noninferiority hazard ratio margin of 1.3. How such a large margin for assessing noninferiority can be justified is not clear.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast
           Cancer—Reply
    • Authors: Ballman KV; McCall LM, Giuliano AE.
      Abstract: In Reply In principle, we agree with Dr Uno and colleagues that restricted mean survival time has the potential for being a more clinically interpretable summary. At this time, few people, especially clinicians, know what this measure is and would need to be educated with respect to its meaning before it would be considered more interpretable.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Trends in Carotid Revascularization Procedures
    • Authors: Hussain MA; Bhatt DL, Al-Omran M.
      Abstract: To the Editor Dr Lichtman and colleagues examined national trends in performance and outcomes of carotid endarterectomy and stenting in the US Medicare population. In a recent time-series analysis examining performance of carotid revascularization in Ontario, Canada, similar trends were noted. Much as in the US Medicare population, a significant decline in carotid endarterectomy and a significant increase in carotid stenting were observed between 2004 and 2006.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Trends in Carotid Revascularization Procedures
    • Authors: Paraskevas KI.
      Abstract: To the Editor In a study of Medicare beneficiaries during 1999-2014, 30-day ischemic stroke or death rates after carotid endarterectomy improved (from 4.4% in 1999-2000 to 3.1% in 2013-2014), as did all-cause mortality (from 1.6% to 1.1%). In contrast, 30-day ischemic stroke or death rates after carotid artery stenting did not differ between the beginning and the end of the study period (7.0% in 1999-2000 and 7.0% in 2013-2014) and neither did all-cause mortality (4.7% in 1999-2000 and 4.8% in 2013-2014). Importantly, 30-day ischemic stroke or death rates after carotid artery stenting were higher than those recommended by the American Heart Association/American Stroke Association (AHA/ASA) guidelines (<6% for symptomatic patients and <3% for asymptomatic patients). This finding was not discussed by the authors.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Trends in Carotid Revascularization Procedures—Reply
    • Authors: Lichtman JH; Howard G, Brott TG.
      Abstract: In Reply Dr Hussain and colleagues point out interesting comparisons in carotid revascularization trends in Ontario, Canada, and in the US Medicare population, including similar 30-day stroke or death outcomes after carotid endarterectomy and stenting. We agree that differing reimbursement policies in the United States and Canada may account for differing patterns of carotid stenting after 2006. A noted difference is the lower receipt of procedures among symptomatic patients in the United States vs Ontario. However, such variation is expected because the approach to asymptomatic treatment has been shown to vary among Western countries.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Risk of Statins for Lower-Risk Individuals
    • Authors: Regenold WT.
      Abstract: To the Editor In a Viewpoint on cholesterol treatment in 2017, Dr Krumholz argued that prescribing statins for secondary prevention of vascular disease or in individuals at higher disease risk is supported by estimates from clinical trials that the number of preventable vascular events over 5 years far exceeds that of anticipated adverse events. He later asserted, without evidence, that “For lower-risk individuals, treatment with statins provides a smaller benefit, but many will find the benefits to outweigh risks.”
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Risks of Statins for Lower-Risk Individuals
    • Authors: Krumholz HM.
      Abstract: In Reply I stand by my statement that “For lower-risk individuals, treatment with statins provides a smaller benefit, but many will find the benefits to outweigh risks.” The lower the absolute risk, the smaller the benefit from statins, but what one person considers a meaningful risk reduction might differ from the view of another. Dr Regenold states that numerous brain disorders are associated with statin use but cites an article that lacks any strong clinical evidence to support that claim. Although it is appropriate to be vigilant in identifying harms of any therapy, physicians must also be careful not to rely on weak evidence and speculation to suggest that there is harm when it has yet to be demonstrated.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Interest in the Ketogenic Diet Grows
    • Authors: Abbasi J.
      Abstract: This Medical News article discusses clinical use of a very-low-carb, high-fat diet for weight loss and type 2 diabetes treatment.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Combination Strategy Associated With Reduced HIV Incidence in Uganda
    • Authors: Friedrich MJ.
      Abstract: The incidence of HIV infection declined with a 2-pronged prevention strategy that combined male circumcision and antiretroviral therapy (ART), report a team of international researchers in the New England Journal of Medicine.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Dangers of Substandard or Falsified Medicines
    • Authors: Friedrich MJ.
      Abstract: Substandard or falsified medications are a growing global threat, particularly in low- and middle-income countries where more than 10% of drugs examined were either substandard or falsified. The scope and scale of the problem are examined in 2 new reports from the World Health Organization (WHO).
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Possible Biomarkers of Deadly Ebola
    • Authors: Friedrich MJ.
      Abstract: Molecular analysis of peripheral blood samples from patients with Ebola virus disease (EVD) identified new mechanisms of pathogenesis and possible biomarkers that may help determine which patients infected with the Ebola virus are most at risk of dying from the disease, according to new research in Cell Host & Microbe.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Injectable Buprenorphine Gets FDA Approval
    • Authors: Voelker R.
      Abstract: The first once-a-month injectable form of buprenorphine has received FDA approval for adults with moderate to severe opioid use disorder (OUD). The drug is indicated for patients who’ve already started treatment with a transmucosal form of buprenorphine and have received a stable dose for at least 7 days.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Regulatory Pathway for 3D Printing
    • Authors: Voelker R.
      Abstract: New guidance is available from the FDA to help medical device manufacturers bring their 3-dimensional (3D)–printed products to market more efficiently.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Second Cancer Biosimilar Approved
    • Authors: Voelker R.
      Abstract: The FDA recently approved the first biosimilar for patients with certain breast or stomach cancers. Marketed as Ogivri, trastuzumab-dkst is the second biosimilar approved in the United States to treat cancer.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Medical Care Use and Expenditures Associated With Adult Obesity in the US
    • Authors: Biener AI; Decker SL, .
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Embers
    • Authors: Halberstadt C.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Appropriations for City Health Departments
    • Abstract: Two years ago, Dr. William C. Woodward, health officer of the District of Columbia, said:
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • Sleeve Gastrectomy for Weight Loss
    • Authors: Puzziferri N; Almandoz JP.
      Abstract: This JAMA Patient Page describes the sleeve gastrectomy procedure as a weight loss treatment for obese persons.
      PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
  • JAMA
    • PubDate: Tue, 16 Jan 2018 00:00:00 GMT
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 23.22.240.119
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016